Although some guidelines recommend use of bisphosphonates (a class of drugs used to strengthen bone) for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those ...
Dec 2, 2014
0
0
Results from a trial of the anti-cancer drug galeterone show that it is successful in lowering prostate-specific antigen (PSA) levels in men with a form of prostate cancer that is resistant to treatment with hormone therapy ...
Nov 18, 2014
0
0
A new study has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. Published in BJU International, ...
Oct 29, 2014
0
0
A widely used treatment for prostate cancer may cause more harm than good for some patients, according to Dr. Oliver Sartor, medical director of the Tulane Cancer Center.
Oct 23, 2014
0
0
(HealthDay)—Mouse models show tissue-specific androgen receptor (AR) signaling is involved in regulation of metabolism, which may explain the link between androgen deprivation therapy (ADT) and the development of metabolic ...
Oct 9, 2014
0
0
The Endocrine Society today issued a Clinical Practice Guideline (CPG) advising against the use of testosterone therapy in healthy women.
Oct 3, 2014
0
0
High-risk prostate cancer patients who receive radiation therapy (RT) and an 18-month course of androgen deprivation therapy (ADT) recover a normal testosterone level in a shorter amount of time compared to those who receive ...
Sep 15, 2014
0
0
Researchers at University of California, San Diego School of Medicine have identified the mechanism by which a rare, inherited neurodegenerative disease causes often crippling muscle weakness in men, in addition to reduced ...
Aug 10, 2014
0
0
Some nutritional sports supplements marketed to athletes—claiming to help them build lean muscle, reduce body fat and enhance endurance—are secretly fortified with androgens, which are banned from use in sports, a new ...
Jun 23, 2014
0
0
Researchers believe they have discovered one reason why some women with estrogen receptor-positive breast cancer may respond poorly or only temporarily to estrogen-blocking drugs such as tamoxifen. Results of a new study, ...
Jun 23, 2014
0
0
